KRAS and neoplasm: As for pancreatic cancer, STAT3 contributes to KRAS-induced PDAC initiation and progression, and inhibition of JAK–STAT3 signaling results in the impairment of a progenitor cell phenotype and abrogation of tumor sphere formation capacity [29–31].